JPH09510358A - 脳−誘導神経栄養因子(bdnf)をコードする組み換えアデノウィルス - Google Patents
脳−誘導神経栄養因子(bdnf)をコードする組み換えアデノウィルスInfo
- Publication number
- JPH09510358A JPH09510358A JP7524417A JP52441795A JPH09510358A JP H09510358 A JPH09510358 A JP H09510358A JP 7524417 A JP7524417 A JP 7524417A JP 52441795 A JP52441795 A JP 52441795A JP H09510358 A JPH09510358 A JP H09510358A
- Authority
- JP
- Japan
- Prior art keywords
- adenovirus
- bdnf
- cell
- dna sequence
- promoter
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- Neurology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Neurosurgery (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.脳−誘導神経栄養因子(BDNF)又はそれらの誘導体をコードするDN A配列を含む欠失組み換えアデノウィルス。 2.DNA配列がプレプロ−BDNFをコードすることを特徴とする請求の範 囲第1項に記載のアデノウィルス。 3.DNA配列がcDNA配列であることを特徴とする請求の範囲第1又は2 項に記載のアデノウィルス。 4.DNA配列がgDNA配列であることを特徴とする請求の範囲第1又は2 項に記載のアデノウィルス。 5.DNA配列がヒトプレプロ−BDNFをコードすることを特徴とする請求 の範囲第1〜4項の1つに記載のアデノウィルス。 6.DNA配列が神経細胞におけるその発現を可能にするシグナルの調節下に おかれることを特徴とする請求の範囲第1〜5項の1つに記載のアデノウィルス 。 7.発現シグナルがウィルスプロモーター、好ましくはE1A、MLP、CM V及びRSV−LTRプロモーターから選ばれることを特徴とする請求の範囲第 6項に記載のアデノウィルス。 8.RSV−LTRプロモーターの調節下でヒトプレプロ−BDNFをコード するcDNA配列を含む欠失組み換えアデノウィルス。 9.RSV−LTRプロモーターの調節下でヒトプレプロ−BDNFをコード するgDNA配列を含む欠失組み換えアデノウィルス。 10.神経細胞における優先的発現を可能にするプロモーターの調節下でヒト 脳−誘導神経栄養因子(hBDNF)又はそれらの誘導体をコードするDNA配 列を含む欠失組み換えアデノウィルス。 11.プロモーターがニューロン−特異的エノラーゼプロモーター及びGFA Pプロモーターから選ばれることを特徴とする請求の範囲第10項に記載の欠失 組み換えアデノウィルス。 12.標的細胞におけるその複製のために必要なそのゲノムの領域が欠けてい ることを特徴とする請求の範囲第1〜11項の1つに記載のアデノウィルス。 13.ITR及び包膜を可能にする配列を含み、E1遺伝子及びE2、E4又 はL1〜L5遺伝子の少なくとも1つが非機能性であることを特徴とする請求の 範囲第12項に記載のアデノウィルス。 14.Ad2又はAd5型ヒトアデノウィルス、あるいはCAV−2型イヌア デノウィルスであることを特徴とする請求の範囲第12又は13項に記載のアデ ノウィルス。 15.神経変性疾患の処置及び/又は予防を目的とする製薬学的組成物の製造 のための請求の範囲第1〜14項の1つに記載のアデノウィルスの利用。 16.パーキンソン病、アルツハイマー病、ハンティングトン舞踏病又はAL S疾患の処置及び/又は予防を目的とする製薬学的組成物の製造のための請求の 範囲第15項に記載の利用。 17.1種又はそれ以上の請求の範囲第1〜14項の1つに記載の欠失組み換 えアデノウィルスを含む製薬学的組成物。 18.注入可能な形態であることを特徴とする請求の範囲第17項に記載の製 薬学的組成物。 19.104〜1014pfu/ml、好ましくは106〜1010pfu/mlの 欠失組み換えアデノウィルスを含むことを特徴とする請求の範 囲第17又は18項に記載の製薬学的組成物。 20.1種又はそれ以上の請求の範囲第1〜14項の1つに記載の欠失組み換 えアデノウィルスに感染した哺乳類細胞。 21.ヒト細胞であることを特徴とする請求の範囲第20項に記載の細胞。 22.繊維芽細胞、筋芽細胞、肝細胞、内皮細胞、神経膠細胞又は表皮細胞型 のヒト細胞であることを特徴とする請求の範囲第20項に記載の細胞。 23.請求の範囲第20〜22項に記載の感染細胞及び細胞外マトリックスを 含む体内押植物。 24.細胞外マトリックスが好ましくはコラーゲン、ゼラチン、グリコサミノ グリカン類、フィブロネクチン及びレクチン類から選ばれるゲル化化合物を含む ことを特徴とする請求の範囲第23項に記載の体内埋植物。 25.細胞外マトリックスが感染細胞の固定を可能にする担体も含むことを特 徴とする請求の範囲第23又は24項に記載の体内埋植物。 26.担体が好ましくはポリテトラフルオロエチレン繊維から成ることを特徴 とする請求の範囲第25項に記載の体内埋植物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9403191A FR2717496B1 (fr) | 1994-03-18 | 1994-03-18 | Virus recombinants, préparation et utilisation en thérapie génique. |
FR94/03191 | 1994-03-18 | ||
PCT/FR1995/000250 WO1995025804A1 (fr) | 1994-03-18 | 1995-03-02 | Adenovirus recombinants codant pour le facteur neurotrophique derive du cerveau (bdnf) |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH09510358A true JPH09510358A (ja) | 1997-10-21 |
Family
ID=9461190
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP7524417A Pending JPH09510358A (ja) | 1994-03-18 | 1995-03-02 | 脳−誘導神経栄養因子(bdnf)をコードする組み換えアデノウィルス |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP0750676A1 (ja) |
JP (1) | JPH09510358A (ja) |
KR (1) | KR970701784A (ja) |
AU (1) | AU703793B2 (ja) |
CA (1) | CA2184200A1 (ja) |
FI (1) | FI963674A (ja) |
FR (1) | FR2717496B1 (ja) |
IL (1) | IL112992A0 (ja) |
MX (1) | MX9603490A (ja) |
NO (1) | NO963559L (ja) |
WO (1) | WO1995025804A1 (ja) |
ZA (1) | ZA952244B (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5830857A (en) * | 1995-07-14 | 1998-11-03 | Amgen Inc. | Method of treating epilepsy |
FR2753379B1 (fr) * | 1996-09-13 | 1998-10-30 | Rhone Poulenc Rorer Sa | Methode de traitement de la sclerose laterale amyotrophique |
CA2408255A1 (en) * | 2000-05-05 | 2001-11-15 | Marie T. Filbin | Methods for stimulating nervous system regeneration and repair by regulating arginase 1 and polyamine synthesis |
WO2019162942A1 (en) * | 2018-02-20 | 2019-08-29 | Carmel Haifa University Economic Corporation Ltd. | Compositions and methods for delivery and expression of small inhibitory peptides and use thereof |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06509094A (ja) * | 1991-07-10 | 1994-10-13 | リジェネロン ファーマシューティカルズ,インコーポレーテッド | Bdnf/nt−3/ngf分子ファミリーのメンバーを用いる運動ニューロン疾患の治療方法 |
US5733871A (en) * | 1991-11-08 | 1998-03-31 | The General Hospital Corporation | Methods for the treatment of neuronal damage associated with ischemia, hypoxia or neurodegeneration |
FR2688514A1 (fr) * | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant. |
AU4995193A (en) * | 1992-08-04 | 1994-03-03 | Regeneron Pharmaceuticals, Inc. | Method of enhancing differentiation and survival of neuronal precursor cells |
DE69334238D1 (de) * | 1992-09-25 | 2008-09-25 | Aventis Pharma Sa | Adenovirus vektoren für die übertragung fremder gene in zellen des zentralen nervensystems, insbesondere im gehirn |
FR2704234B1 (fr) * | 1993-04-22 | 1995-07-21 | Centre Nat Rech Scient | Virus recombinants, preparation et utilisation en therapie genique. |
-
1994
- 1994-03-18 FR FR9403191A patent/FR2717496B1/fr not_active Expired - Fee Related
-
1995
- 1995-03-02 CA CA002184200A patent/CA2184200A1/fr not_active Abandoned
- 1995-03-02 KR KR1019960705207A patent/KR970701784A/ko not_active Application Discontinuation
- 1995-03-02 MX MX9603490A patent/MX9603490A/es not_active Application Discontinuation
- 1995-03-02 EP EP95911371A patent/EP0750676A1/fr not_active Ceased
- 1995-03-02 AU AU18962/95A patent/AU703793B2/en not_active Ceased
- 1995-03-02 JP JP7524417A patent/JPH09510358A/ja active Pending
- 1995-03-02 WO PCT/FR1995/000250 patent/WO1995025804A1/fr not_active Application Discontinuation
- 1995-03-14 IL IL11299295A patent/IL112992A0/xx unknown
- 1995-03-17 ZA ZA952244A patent/ZA952244B/xx unknown
-
1996
- 1996-08-26 NO NO963559A patent/NO963559L/no not_active Application Discontinuation
- 1996-09-17 FI FI963674A patent/FI963674A/fi not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
FI963674A0 (fi) | 1996-09-17 |
NO963559L (no) | 1996-08-26 |
AU703793B2 (en) | 1999-04-01 |
FI963674A (fi) | 1996-09-17 |
EP0750676A1 (fr) | 1997-01-02 |
FR2717496A1 (fr) | 1995-09-22 |
FR2717496B1 (fr) | 1996-04-12 |
ZA952244B (en) | 1996-01-16 |
AU1896295A (en) | 1995-10-09 |
CA2184200A1 (fr) | 1995-09-28 |
WO1995025804A1 (fr) | 1995-09-28 |
IL112992A0 (en) | 1995-06-29 |
KR970701784A (ko) | 1997-04-12 |
MX9603490A (es) | 1997-03-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6245330B1 (en) | Recombinant adenoviruses coding for glial-derived neurotrophic factor (GDNF) | |
DE69531387T2 (de) | Von Adenovirus abgeleitete rekombinante Vektoren, für Gentherapie | |
US20010012516A1 (en) | Viral vectors | |
US6040172A (en) | Defective DNA viral vector comprising a neural tissue-specific promoter for in vivo expression of a gene | |
JPH09510621A (ja) | 塩基性繊維芽細胞増殖因子(bFGF)をコードする組換えアデノウイルス | |
US20040224409A1 (en) | Recombinant adenoviruses coding for brain-derived neurotrophic factor (BDNF) | |
JP2000178207A (ja) | 家庭動物及び家畜の貧血治療におけるエリスロポイエチンの使用 | |
JPH09510357A (ja) | 酸性繊維芽細胞成長因子(aFGF)をコードする組み換えアデノウィルス | |
Vasquez et al. | Replication-Deficient Adenovirus Vector Transfer ofgfpReporter Gene into Supraoptic Nucleus and Subfornical Organ Neurons | |
JPH10501402A (ja) | 肝臓特異的遺伝子治療のためのベクター | |
JPH09510358A (ja) | 脳−誘導神経栄養因子(bdnf)をコードする組み換えアデノウィルス | |
RU2725830C1 (ru) | Композиция для облегчения или лечения боли | |
CN111909246B (zh) | 高效感染支持细胞的aav突变体 | |
US20020031493A1 (en) | Recombinant adenoviruses coding for glial-derived cell neurotrophic factor (gdnf) | |
JP2001504088A (ja) | 筋委縮性側索硬化症の治療方法 | |
US20220233715A1 (en) | Aav mutant that efficiently infects supporting cells | |
HUT56881A (en) | Process for expressing human nerve growth factor in arthropoda frugiperda cells infected with recombinant baculovirus | |
JPH09510356A (ja) | 神経膠細胞成熟因子ベータ型(GMF−β)のための組み換えアデノウィルス | |
US20030148952A1 (en) | Methods and materials for the recruitment of endothelial cells | |
CN108727484A (zh) | 人血清淀粉样蛋白a1功能性短肽及其制备方法和应用 | |
JPH09509059A (ja) | アルツハイマー病の動物モデル、調製方法および使用 | |
JPH09501306A (ja) | 血友病の遺伝子療法 | |
WO1999036559A1 (en) | Viral vectors expressing self-polymerizing neuronal intermediate filaments and their use | |
WO1994019462A1 (fr) | Facteurs de croissance de la famille de l'harp, procede d'obtention et applications | |
JP2002524468A (ja) | プロサポシン受容体活性を刺激する方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20041207 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20050307 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20050418 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050607 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050607 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20051206 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060404 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060519 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20060608 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20070111 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20080704 |